Sugi Predict

Sugi Predict / Compounds / SCHEMBL20558149

SCHEMBL20558149

SCHEMBL20558149

CC(C)c1cnn2c(O)nc(-c3cncc(F)c3)nc12

nearest known ligand 0.49

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 1/20 0.49
▸ CYP11B1 P15538 2/20 0.32
▸ CYP11B2 P19099 2/20 0.32
▸ CYP17A1 P05093 1/20 0.32
▸ CYP3A4 P08684 1/20 0.32
▸ RPS6KA3 P51812 1/20 0.31
▸ CDK7 P50613 2/20 0.31
▸ TLR7 Q9NYK1 1/20 0.30
▸ CHRNB2 P17787 1/20 0.30
▸ CHRNB4 P30926 1/20 0.30
▸ CHRNA3 P32297 1/20 0.30
▸ CHRNA7 P36544 1/20 0.30
▸ CHRNA4 P43681 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29619215 0.85 AHR (0.49) AHRCYP11B1CYP11B2CYP17A1CYP3A4
SCHEMBL20541825 0.85 AHR (0.49) AHRCYP11B1CYP11B2CYP17A1CYP3A4
SCHEMBL21754321 0.85 AHR (0.49) AHRCYP11B1CYP11B2CDK7TLR7
SCHEMBL21855501 0.83 AHR (0.35) AHRCYP11B1CYP11B2CYP17A1CYP3A4
SCHEMBL30579319 0.83 CYP11B2 (0.36) AHRCYP11B1CYP11B2CYP17A1CYP3A4
SCHEMBL20542249 0.83 CYP11B2 (0.36) AHRCYP11B1CYP11B2CYP17A1CYP3A4
SCHEMBL23771447 0.83 AHR (0.56) AHRCYP11B1CYP11B2CDK7TLR7
SCHEMBL21855486 0.81 CYP11B2 (0.33) AHRCYP11B1CYP11B2CYP17A1CYP3A4
SCHEMBL20557427 0.80 AHR (0.41) AHRCYP11B1CYP11B2CYP17A1CYP3A4
SCHEMBL20557960 0.80 AHR (0.33) AHRCYP11B1CYP11B2CYP17A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4710923-A2 INDOLE AHR INHIBITORS AND USES THEREOF Ikena Oncology, Inc. (US) 2026-03-18 — — EP disclosed
EP-3612030-B1 INDOLE AHR INHIBITORS AND USES THEREOF IKENA ONCOLOGY INC (US) 2025-12-24 — — EP disclosed
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2025-04-17 — — US disclosed
US-12077542-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2024-09-03 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 — — US disclosed
CN-110831600-A Indole AHR inhibitors and uses thereof 金恩医疗公司 2020-02-21 — — CN disclosed
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2018-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180327411-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 AHR 1/4885CYP11B1 77/4885CYP11B2 86/4885
US-10570138-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 AHR 1/4885CYP11B1 77/4885CYP11B2 86/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 AHR 1/4885CYP11B1 77/4885CYP11B2 86/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 AHR 1/4885CYP11B1 77/4885CYP11B2 86/4885
US-10689388-B1 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 AHR 1/4885CYP11B1 77/4885CYP11B2 86/4885
US-20250122205-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 AHR 1/4885CYP11B1 77/4885CYP11B2 86/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 AHR 1/4885CYP11B1 77/4885CYP11B2 86/4885
US-12077542-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 AHR 1/4885CYP11B1 77/4885CYP11B2 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.